San Diego-based National Resilience, a new manufacturing and technology company focused on making sure countries can manufacture their own vaccines and other threapeutics, says it has received $163.8M in a funding from the Government of Canada, to modernize and expand its Ontario, Canada biomanufacturing site. The company said the move is part of Canada's efforts to improve in pandemic preparedness. Resilience was founded during the pandemic, in 2020, and says it is building a network of high-tech, end-to-end manufacturing solutions to ensure medicines can be made quickly, safely, and at scale. The company says its purpose is to protect biopharmaceutical supply chains against disruption. Resilience said the investment by Canada will maintain 295 existing jobs and create 205 new full-time positions at the Mississauga facility. National Resilience has raised more than $800M in venture capital funding, with funding from ARCH Venture Partners, 8VC, GV, and NEA. The company's CEO, Raul Singhvi, is the former CEo of Novavax. The company just launched in November of 2020, and also owns a former Genzyme manufacturing plant in Boston.